Home/Pipeline/CYT‑101

CYT‑101

Recurrent Glioblastoma Multiforme

Phase 1Active

Key Facts

Indication
Recurrent Glioblastoma Multiforme
Phase
Phase 1
Status
Active
Company

About Cyteph

Cyteph creates off‑the‑shelf allogeneic CMV‑specific CAR‑T therapies for solid tumours, starting with glioblastoma.

View full company profile

Therapeutic Areas

Other Recurrent Glioblastoma Multiforme Drugs

DrugCompanyPhase
BerubicinCNS PharmaceuticalsPhase 2